Splenic Vein Diameter is a Risk Factor for the Portal Venous System Thrombosis After Partial Splenic Artery Embolization.
Adolescent
Adult
Aged
Aged, 80 and over
Child
Embolization, Therapeutic
/ adverse effects
Female
Humans
Male
Middle Aged
Portal Vein
/ physiopathology
Retrospective Studies
Risk Factors
Splenic Artery
/ physiopathology
Splenic Vein
/ anatomy & histology
Tomography, X-Ray Computed
/ methods
Venous Thrombosis
/ etiology
Young Adult
Infarcted splenic percentage
Maximum diameter of the splenic vein
Partial splenic artery embolization
Portal vein thrombosis
Portal venous system thrombosis
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
15
06
2020
accepted:
16
12
2020
pubmed:
22
1
2021
medline:
13
7
2021
entrez:
21
1
2021
Statut:
ppublish
Résumé
Portal venous system thrombosis is a complication of partial splenic artery embolization, and pre-treatment risk assessment is thus important. The purpose of this study was to identify the risk factors for portal venous system thrombosis after partial splenic artery embolization. We retrospectively analyzed 67 consecutive patients who underwent contrast-enhanced computed tomography before and after first partial splenic artery embolization between July 2007 and October 2018. As risk factors, we investigated age, sex, hematological data, liver function, steroid use, heparin use, and findings from pre- and post-treatment computed tomography. Uni- and multivariate analyses were performed to evaluate the relationship between thrombus appearance or growth and these factors. Values of p < 0.05 were considered significant. Partial splenic artery embolization was technically successful in all 67 patients. Nine patients showed appearance or growth of thrombus. Univariate analysis showed maximum diameter of the splenic vein before treatment (p = 0.0076), percentage of infarcted spleen (p = 0.017), and volume of infarcted spleen (p = 0.022) as significant risk factors. Multivariate analysis showed significant differences in maximum diameter of the splenic vein before treatment (p = 0.041) and percentage of infarcted spleen (p = 0.023). According to receiver operating characteristic analysis, cutoffs for maximum diameter of the splenic vein and percentage of infarcted spleen for distinguishing the appearance or growth of thrombus were 17 mm and 58.2%. Large maximum diameter of the splenic vein before partial splenic artery embolization and high percentage of infarcted spleen after partial splenic artery embolization were identified as risk factors for portal venous system thrombosis. Level 4, Case Series.
Identifiants
pubmed: 33474605
doi: 10.1007/s00270-020-02751-8
pii: 10.1007/s00270-020-02751-8
pmc: PMC8172394
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
921-930Références
Hayashi H, Beppu T, Okabe K, Masuda T, Okabe H, Baba H. Risk factors for complications after partial splenic embolization for liver cirrhosis. Br J Surg. 2008;95:744–50.
doi: 10.1002/bjs.6081
Cai M, Huang W, Lin C, Li Z, Qian J, Huang M, et al. Partial splenic embolization for thrombocytopenia in liver cirrhosis: predictive factors for platelet increment and risk factors for major complications. Eur Radiol. 2016;26:370–80.
doi: 10.1007/s00330-015-3839-4
Matsumoto T, Yamagami T, Terayama K, Kato T, Hirota T, Yoshimatsu R, et al. Risk factors and clinical course of portal and/or splenic vein thrombosis after partial splenic embolization. Acta radiol. 2009;50:617–23.
doi: 10.1080/02841850902922779
Zhu K, Meng X, Qian J, Huang M, Li Z, Guan S, et al. Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients. Dig Liver Dis. 2009;41:411–6.
doi: 10.1016/j.dld.2008.10.005
N’Kontchou G, Seror O, Bourcier V, Mohand D, Ajavon Y, Castera L, et al. Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. Eur J Gastroenterol Hepatol. 2005;17:179–84.
doi: 10.1097/00042737-200502000-00008
Alwmark A, Bengmark S, Gullstrand P, Joelsson B, Lunderquist A, Owman T. Evaluation of splenic embolization in patients with portal hypertension and hypersplenism. Ann Surg. 1982;196:518–24.
doi: 10.1097/00000658-198211000-00003
Cai M, Zhu K, Huang W, Meng X, He K, Zhou B, et al. Portal vein thrombosis after partial splenic embolization in liver cirrhosis: efficacy of anticoagulation and long-term follow-up. J Vasc Interv Radiol. 2013;24:1808–16.
doi: 10.1016/j.jvir.2013.08.018
Sakai T, Shiraki K, Inoue H, Sugimoto K, Ohmori S, Murata K, et al. Complications of partial splenic embolization in cirrhotic patients. Dig Dis Sci. 2002;47:388–91.
doi: 10.1023/A:1013786509418
Rajani R, Björnsson E, Bergquist A, Danielsson Å, Gustavsson A, Grip O, et al. The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Aliment Pharmacol Ther. 2010;32:1154–62.
doi: 10.1111/j.1365-2036.2010.04454.x
Cool J, Rosenblatt R, Kumar S, Lucero C, Fortune B, Crawford C, et al. Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort. J Gastroenterol Hepatol. 2019;34:1088–92.
doi: 10.1111/jgh.14501
Englesbe MJ. Portal vein thrombosis and survival in patients with cirrhosis. Liv Transpl. 2010;16:83–90.
doi: 10.1002/lt.21941
Haag K, Rössle M, Ochs A, Huber M, Siegerstetter V, Olschewski M, et al. Correlation of duplex sonography findings and portal pressure in 375 patients with portal hypertension. Am J Roentgenol. 1999;172:631–5.
doi: 10.2214/ajr.172.3.10063849
Maruyama H, Shiba M, Ishikawa-Kakiya Y, Kato K, Ominami M, Fukunaga S, et al. Positive correlation between pancreatic volume and postendoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2020;35:769–76.
doi: 10.1111/jgh.14878
Kageyama K, Nishida N, Yamamoto A, Jogo A, Tsukamoto T, Miki Y. Usefulness of CT volumetry for gastric varix before balloon-occluded retrograde transvenous obliteration. Hepatogastroenterology. 2014;61:1806–11.
pubmed: 25436383
Tsamalaidze L, Stauffer JA, Brigham T, Asbun HJ. Postsplenectomy thrombosis of splenic, mesenteric, and portal vein (PST-SMPv): a single institutional series, comprehensive systematic review of a literature and suggested classification. Am J Surg. 2018;216:1192–204.
doi: 10.1016/j.amjsurg.2018.01.073
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. A nssessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—The albi grade. J Clin Oncol. 2015;33:550–8.
doi: 10.1200/JCO.2014.57.9151
Danno K, Ikeda M, Sekimoto M, Sugimoto T, Takemasa I, Yamamoto H, et al. Diameter of splenic vein is a risk factor for portal or splenic vein thrombosis after laparoscopic splenectomy. Surgery. 2009;145:457–64.
doi: 10.1016/j.surg.2008.06.030
Kinjo N, Kawanaka H, Akahoshi T, Tomikawa M, Yamashita N, Konishi K, et al. Risk factors for portal venous thrombosis after splenectomy in patients with cirrhosis and portal hypertension. Br J Surg. 2010;97:910–6.
doi: 10.1002/bjs.7002
Kuroki T, Kitasato A, Tokunaga T, Takeshita H, Taniguchi K, Maeda S, et al. Predictors of portal and splenic vein thrombosis after laparoscopic splenectomy: a retrospective analysis of a single-center experience. Surg Today. 2018;48:804–9.
doi: 10.1007/s00595-018-1655-6
de’Angelis N, Abdalla S, Lizzi V, Esposito F, Genova P, Roy L, et al. Incidence and predictors of portal and splenic vein thrombosis after pure laparoscopic splenectomy. Surgery. 2017;162:1219–30.
doi: 10.1016/j.surg.2017.07.016
Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology. 2017;153:480–7.
doi: 10.1053/j.gastro.2017.04.042
Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Shinohara F, Nakamura Y, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48:51–8.
doi: 10.1111/hepr.12895
Hidaka H, Kokubu S, Sato T, Katsushima S, Izumi N, Igura T, et al. Antithrombin III for portal vein thrombosis in patients with liver disease: a randomized, double-blind, controlled trial. Hepatol Res. 2018;48:E107–16.
doi: 10.1111/hepr.12934